Bone Biologics (NASDAQ:BBLG) reported quarterly losses of $(1.33) per share which missed the analyst consensus estimate of $(0.58) by 129.31 percent. This is a 66.92 percent increase over losses of $(4.02) per share from the same period last year.
Bone Biologics (NASDAQ:BBLG) reported quarterly losses of $(1.33) per share which missed the analyst consensus estimate of $(0.58) by 129.31 percent. This is a 66.92 percent increase over losses of $(4.02) per share from the same period last year.
Comments